Cargando…
Autoregulation of H(+)/lactate efflux prevents monocarboxylate transport (MCT) inhibitors from reducing glycolytic lactic acid production
BACKGROUND: Pharmacological inhibition of membrane transporters is expected to reduce the flow of solutes, unless flux is restored (i.e., autoregulated) through a compensatory increase in the transmembrane driving force. Drugs acting on monocarboxylate transporters (MCTs) have been developed to disr...
Autores principales: | Blaszczak, Wiktoria, Williams, Hannah, Swietach, Pawel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519749/ https://www.ncbi.nlm.nih.gov/pubmed/35840734 http://dx.doi.org/10.1038/s41416-022-01910-7 |
Ejemplares similares
-
Permeability and driving force: why is it difficult to control glycolytic flux by blocking lactate transporters?
por: Blaszczak, Wiktoria, et al.
Publicado: (2023) -
Monocarboxylate Transporter 1 (MCT1) in Liver Pathology
por: Droździk, Marek, et al.
Publicado: (2020) -
Natural Autoimmunity to the Thyroid Hormone Monocarboxylate Transporters MCT8 and MCT10
por: Porst, Theresa, et al.
Publicado: (2021) -
Crucial Residue Involved in L-Lactate Recognition by Human Monocarboxylate Transporter 4 (hMCT4)
por: Sasaki, Shotaro, et al.
Publicado: (2013) -
Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer
por: Latif, Ayşe, et al.
Publicado: (2017)